These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9673943)

  • 1. Further development of a recombinant feline herpesvirus type 1 vector expressing feline calicivirus immunogenic antigen.
    Yokoyama N; Fujita K; Damiani A; Sato E; Kurosawa K; Miyazawa T; Ishiguro S; Mochizuki M; Maeda K; Mikami T
    J Vet Med Sci; 1998 Jun; 60(6):717-23. PubMed ID: 9673943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine efficacy of recombinant feline herpesvirus type 1 expressing immunogenic proteins of feline calicivirus in cats.
    Yokoyama N; Maeda K; Fujita K; Ishiguro S; Sagawa T; Mochizuki M; Tohya Y; Mikami T
    Arch Virol; 1996; 141(12):2339-51. PubMed ID: 9526541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant feline herpesvirus type 1 expressing immunogenic proteins inducible virus neutralizing antibody against feline calicivirus in cats.
    Yokoyama N; Maeda K; Tohya Y; Kawaguchi Y; Fujita K; Mikami T
    Vaccine; 1996 Dec; 14(17-18):1657-63. PubMed ID: 9032896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of serologic tests to predict resistance to feline herpesvirus 1, feline calicivirus, and feline parvovirus infection in cats.
    Lappin MR; Andrews J; Simpson D; Jensen WA
    J Am Vet Med Assoc; 2002 Jan; 220(1):38-42. PubMed ID: 12680445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenicity and vaccine efficacy of a thymidine kinase-deficient mutant of feline herpesvirus type 1 in cats.
    Yokoyama N; Maeda K; Tohya Y; Kawaguchi Y; Shin YS; Ono M; Ishiguro S; Fujikawa Y; Mikami T
    Arch Virol; 1996; 141(3-4):481-94. PubMed ID: 8645090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-exposure treatment of cats with mouse-cat chimeric antibodies against feline herpesvirus type 1 and feline calicivirus.
    Umehashi M; Imamura T; Akiyama S; Kimachi K; Tokiyoshi S; Mikami T
    J Vet Med Sci; 2002 Nov; 64(11):1017-21. PubMed ID: 12499687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Onset of immunity in kittens after vaccination with a non-adjuvanted vaccine against feline panleucopenia, feline calicivirus and feline herpesvirus.
    Jas D; Aeberlé C; Lacombe V; Guiot AL; Poulet H
    Vet J; 2009 Oct; 182(1):86-93. PubMed ID: 18694649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-year duration of immunity for feline herpesvirus and calicivirus evaluated in a controlled vaccination-challenge laboratory trial.
    Jas D; Frances-Duvert V; Vernes D; Guigal PM; Poulet H
    Vet Microbiol; 2015 May; 177(1-2):123-31. PubMed ID: 25824128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient expression of the envelope protein of feline immunodeficiency virus in a recombinant feline herpesvirus type 1 (FHV-1) using the gC promoter of FHV-1.
    Sato E; Yokoyama N; Miyazawa T; Maeda K; Ikeda Y; Nishimura Y; Fujita K; Kohmoto M; Takahashi E; Mikami T
    Virus Res; 2000 Sep; 70(1-2):13-23. PubMed ID: 11074121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of chimeric feline foamy virus-based retroviral vectors for the induction of antiviral immunity in cats.
    Schwantes A; Truyen U; Weikel J; Weiss C; Löchelt M
    J Virol; 2003 Jul; 77(14):7830-42. PubMed ID: 12829823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-exposure treatment of cats with anti-FHV-1 and anti-FCV mouse-cat chimeric antibodies.
    Umehashi M; Imamura T; Akiyama S; Matsuda J; Tokiyoshi S; Tohya Y; Mikami T
    J Vet Med Sci; 2003 May; 65(5):563-6. PubMed ID: 12808206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term immunity in cats vaccinated with an inactivated trivalent vaccine.
    Scott FW; Geissinger CM
    Am J Vet Res; 1999 May; 60(5):652-8. PubMed ID: 10328440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feline panleukopenia virus, feline herpesvirus-1, and feline calicivirus antibody responses in seronegative specific pathogen-free cats after a single administration of two different modified live FVRCP vaccines.
    Lappin MR; Veir J; Hawley J
    J Feline Med Surg; 2009 Feb; 11(2):159-62. PubMed ID: 18782676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of serum antibody titres against feline panleukopenia, herpesvirus and calicivirus infections in stray cats of Milan, Italy.
    Dall'Ara P; Labriola C; Sala E; Spada E; Magistrelli S; Lauzi S
    Prev Vet Med; 2019 Jun; 167():32-38. PubMed ID: 31027718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycoproteins gl and gE of feline herpesvirus-1 are virulence genes: safety and efficacy of a gl-gE deletion mutant in the natural host.
    Kruger JM; Sussman MD; Maes RK
    Virology; 1996 Jun; 220(2):299-308. PubMed ID: 8661381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Questions long-term immunity in cats.
    Norsworthy GD
    J Am Vet Med Assoc; 1999 Aug; 215(3):316-7. PubMed ID: 10434959
    [No Abstract]   [Full Text] [Related]  

  • 17. Feline panleukopenia virus, feline herpesvirus-1 and feline calicivirus antibody responses in seronegative specific pathogen-free kittens after parenteral administration of an inactivated FVRCP vaccine or a modified live FVRCP vaccine.
    Lappin MR
    J Feline Med Surg; 2012 Feb; 14(2):161-4. PubMed ID: 22314095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Questions efficacy of vaccinating cats at 3-year intervals.
    Norsworthy GD
    Am J Vet Res; 1999 Aug; 60(8):918-9. PubMed ID: 10451196
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of a single dose of an intranasal feline herpesvirus 1, calicivirus, and panleukopenia vaccine on clinical signs and virus shedding after challenge with virulent feline herpesvirus 1.
    Lappin MR; Sebring RW; Porter M; Radecki SJ; Veir J
    J Feline Med Surg; 2006 Jun; 8(3):158-63. PubMed ID: 16442823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of an avirulent FCV strain with a broad serum cross-neutralization profile and protection against challenge of a highly virulent vs feline calicivirus.
    Rong S; Lowery D; Floyd-Hawkins K; King V
    Virus Res; 2014 Aug; 188():60-7. PubMed ID: 24685673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.